[go: up one dir, main page]

IL103059A0 - Conjugates for introducing nucleic acid into higher eucaryotic cells - Google Patents

Conjugates for introducing nucleic acid into higher eucaryotic cells

Info

Publication number
IL103059A0
IL103059A0 IL103059A IL10305992A IL103059A0 IL 103059 A0 IL103059 A0 IL 103059A0 IL 103059 A IL103059 A IL 103059A IL 10305992 A IL10305992 A IL 10305992A IL 103059 A0 IL103059 A0 IL 103059A0
Authority
IL
Israel
Prior art keywords
conjugates
nucleic acid
cell
introducing nucleic
eucaryotic cells
Prior art date
Application number
IL103059A
Original Assignee
Boehringer Ingelheim Int
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Univ North Carolina filed Critical Boehringer Ingelheim Int
Publication of IL103059A0 publication Critical patent/IL103059A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Conjugates in which a virus is bound via an antibody to a substance with affinity for nucleic acids in order to transport gene constructs into higher eukaryotic cells. Complexes of the conjugates and nucleic acid are, where appropriate with the cooperation of a cell type-specific internalisation factor, internalised into the cell, where the virus, as constituent of the complex, brings about the internalisation as well as the release of the contents of the endosomes in which the complexes are located after entry into the cell. Pharmaceutical compositions in which the nucleic acid is a therapeutically effective gene construct, especially for use in gene therapy, and transfection kits. <IMAGE>
IL103059A 1991-09-30 1992-09-04 Conjugates for introducing nucleic acid into higher eucaryotic cells IL103059A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76778791A 1991-09-30 1991-09-30
US82704992A 1992-01-30 1992-01-30
US86475892A 1992-04-07 1992-04-07

Publications (1)

Publication Number Publication Date
IL103059A0 true IL103059A0 (en) 1993-02-21

Family

ID=27419640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL103059A IL103059A0 (en) 1991-09-30 1992-09-04 Conjugates for introducing nucleic acid into higher eucaryotic cells

Country Status (15)

Country Link
EP (2) EP0606280B1 (en)
JP (1) JP3479298B2 (en)
CN (1) CN1071457A (en)
AT (1) ATE187497T1 (en)
AU (1) AU669335B2 (en)
CA (1) CA2114800A1 (en)
DE (1) DE59209778D1 (en)
FI (1) FI941473A7 (en)
HU (2) HUT71322A (en)
IL (1) IL103059A0 (en)
MX (1) MX9205226A (en)
NO (1) NO941155L (en)
NZ (1) NZ244291A (en)
TW (1) TW249247B (en)
WO (1) WO1993007282A1 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
AU6568594A (en) * 1993-04-14 1994-11-08 Boehringer Mannheim Gmbh Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
DE4335025A1 (en) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytically active particles
EP0648493A1 (en) * 1993-10-19 1995-04-19 Tadatsugu Prof. Dr. Taniguchi A method to reverse the phenotype of transformed cells by the transcription factor IRF-1
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
DE4426429A1 (en) * 1994-07-26 1996-02-01 Boehringer Ingelheim Int Method for introducing DNA into higher eukaryotic cells
DK0705903T3 (en) 1994-08-12 2001-08-27 Myriad Genetics Inc Mutations in the 17q-linked breast and ovarian cancer predisposition
AU691331B2 (en) 1994-08-12 1998-05-14 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5780009A (en) * 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
AU5979296A (en) * 1995-06-07 1996-12-30 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU1461597A (en) 1995-12-18 1997-07-14 Endorecherche Inc. Chromosome 13-linked breast cancer susceptibility gene
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
AU714527B2 (en) 1995-12-22 2000-01-06 University Of Utah Research Foundation KVLQT1 - A long QT syndrome gene which encodes KVLQT1 which coassembles with minK to form cardiac 1ks potassium channels
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
DE19649645A1 (en) * 1996-11-29 1998-06-04 Hoechst Ag Multiple functional ligand system for target cell-specific transfer of nucleotide sequences
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB9712512D0 (en) 1997-06-16 1997-08-20 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
EP1003711B1 (en) 1997-08-13 2001-11-07 Biontex Laboratories GmbH Novel lipopolyamines, and the preparation and use thereof
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
PT1944371E (en) 1998-05-01 2015-07-13 Novartis Ag Neisseria meningitidis antigens and compositions
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
DE19845420C2 (en) * 1998-10-02 2000-11-16 Deutsches Krebsforsch Intercellular spread of recombinant DNA
AU1316200A (en) 1998-10-15 2000-05-01 Chiron Corporation Metastatic breast and colon cancer regulated genes
AU772847B2 (en) 1998-11-12 2004-05-06 Invitrogen Corporation Transfection reagents
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1961813B1 (en) 1998-12-16 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Human cyclin-dependent kinase (hPNQALRE)
EP2290083B1 (en) 1999-04-30 2014-08-20 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2003520248A (en) 2000-01-17 2003-07-02 カイロン エセ．ピー．アー． N. Outer Membrane Vesicle (OMV) Vaccine Comprising MENINGITIDIS Serotype B Outer Membrane Protein
EP1790660B1 (en) 2000-02-28 2012-06-20 Novartis Vaccines and Diagnostics S.r.l. Heterologous expression of neisserial proteins
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
DE60138403D1 (en) 2000-09-26 2009-05-28 Crucell Holland Bv ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST
NZ594877A (en) 2000-10-27 2012-07-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
EP1349924A2 (en) 2000-11-03 2003-10-08 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilites and defective dna repair mechanisms and treatment thereof
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1372704B1 (en) 2001-03-30 2008-10-15 Ghc Research Development Corporation Monocyte-specific particulate delivery vehicle
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
MXPA04008891A (en) 2002-04-25 2004-11-26 Crucell Holland Bv Means and methods for the production of adenovirus vectors.
AU2003230027A1 (en) 2002-05-17 2003-12-02 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP2287341B1 (en) 2003-12-01 2013-02-13 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
WO2005067708A2 (en) 2004-01-14 2005-07-28 Daniolabs Limited Zebrafish model for autoimmune diseases
WO2005093064A1 (en) 2004-03-29 2005-10-06 Galpharma Co., Ltd. Novel galectin 9 modification protein and use thereof
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US8999944B2 (en) 2005-01-20 2015-04-07 University Of Rochester Thioredoxin interacting protein (TXNIP) as regulator of vascular function
JP2009522281A (en) 2005-12-28 2009-06-11 トランスレーショナル セラピューティクス，インク． Treatment based on translational dysfunction
JP2009532057A (en) 2006-04-07 2009-09-10 ニューロ セラピューティクス エービー Neuronal survival and development
US7723564B2 (en) 2006-05-10 2010-05-25 Board Of Regents Of The University Of Nebraska Compositions and methods for modulation of KSR1 and KSR2 interactions
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008116116A2 (en) 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
US8772238B2 (en) 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
GB0908425D0 (en) 2009-05-15 2009-06-24 Medical Res Council Medical use
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
GB201012651D0 (en) 2010-07-28 2010-09-15 Univ Edinburgh Peptides
EP2658567A4 (en) 2010-12-28 2014-09-24 Univ Rochester METHODS OF MODIFYING INSULIN SIGNALING USING BILIVERDINE REDUCTASE (BVR) AND PEPTIDES DERIVED FROM ISR
EP3741384A1 (en) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase and cell differentiation
EP2908853B1 (en) 2012-10-21 2018-12-05 University Of Rochester Thy1 (cd90) as a therapy to control adipose tissue accumulation
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
CN116966310A (en) 2014-05-14 2023-10-31 塔歌牧恩治疗公司 Improved polyethyleneimine polyethylene glycol carrier
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
US11273151B2 (en) 2015-11-04 2022-03-15 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
CN111413499B (en) * 2020-04-17 2023-06-27 中国兽医药品监察所 A kind of indirect immunofluorescence kit for detection of poultry adenovirus group I

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof

Also Published As

Publication number Publication date
CA2114800A1 (en) 1993-04-15
AU2593292A (en) 1993-05-03
NO941155D0 (en) 1994-03-29
FI941473A0 (en) 1994-03-30
JPH07500009A (en) 1995-01-05
MX9205226A (en) 1993-03-01
EP0606280A1 (en) 1994-07-20
CN1071457A (en) 1993-04-28
HU9400899D0 (en) 1994-06-28
ATE187497T1 (en) 1999-12-15
NZ244291A (en) 1995-07-26
TW249247B (en) 1995-06-11
NO941155L (en) 1994-03-29
HU211902A9 (en) 1996-01-29
FI941473A7 (en) 1994-03-30
EP0535576A1 (en) 1993-04-07
WO1993007282A1 (en) 1993-04-15
AU669335B2 (en) 1996-06-06
HUT71322A (en) 1995-11-28
DE59209778D1 (en) 2000-01-13
EP0606280B1 (en) 1999-12-08
JP3479298B2 (en) 2003-12-15

Similar Documents

Publication Publication Date Title
IL103059A0 (en) Conjugates for introducing nucleic acid into higher eucaryotic cells
IL103171A0 (en) Composition for introducing nucleic acid complexes into higher eucaryotic cells
DE59207189D1 (en) NEW COMPLEXES CONTAINED BY ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID
JPH0688913B2 (en) Molecular conjugate containing cell membrane blending agent
AU637085B2 (en) New transferrin-polycation conjugates
GB2286593A (en) Virus with modified binding moiety specific for the target cells
US5922859A (en) Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
PT1244805E (en) DISTRIBUTION COMPLEXES OF CATIONIC PROTEIN-LIPID-NUCLEIC ACID OF THE VIRAL NUCLEUS
WO1994006923A1 (en) Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
GR3036634T3 (en) Novel protein polycation conjugates.
CA2189051A1 (en) Composition for delivery of toxic radioisotopes to the cell nucleus and use
GR3035006T3 (en) New conjugates, consisting of a glycoprotein and a nucleic acid-binding substance.
AU8818398A (en) Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
AU3354795A (en) Gene-Containing Compositions
AU705060B2 (en) Improved pharmaceutical compositions
CDCA H3. 1 GFP H3. 2
JPH03501684A (en) Method for producing HIV antigen and its system